CHCWM – Cancer & Hematology Centers of West Michigan

CPI-0209-01 (Constellation)

CPI-0209-01 (Constellation)

Description:   A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors

Mechanism of Action:  EZH2  Inhibitor

Target Patient Population:  In Phase 2 with slots for tumors with known ARID1A mutations in Lymphoma, Mesothelioma, Urothelial and Endometrial. 

Study Design:  Drug is given orally daily.